ResultsCX Achieves Coveted Great Place to Work® Certification™ Across Five Countries

Indica Labs Announces AI-Powered HALO® Software Release for Digital Pathology Research in Life Sciences

Indica Labs announced today the release of the transformative new version of its industry leading life sciences software.

SPT Labtech’s firefly® liquid handler chosen by Colossal Biosciences to accelerate NGS capabilities in fight against species extinction and biodiversity loss

Creative Enzymes Introduces Leaf-branch Compost Poly (ethylene terephthalate) Hydrolase for Sustainable PET Degradation

Study Demonstrates MyPhenome Hungry Gut Test Identifies Responders to Semaglutide

New independent study’s findings presented during Presidential Plenary session at Digestive Disease Week 2024.

Integrated DNA Technologies Invests in New U.S. Synthetic Biology Manufacturing Facility

Creative Enzymes Introduces Recombinant Porcine Citrate Synthase with Enhanced C-His Tag for Accelerated Metabolic Research

SPT Labtech and Watchmaker Genomics Partner to Simplify and Streamline NGS Library Preparation

PathAI and Aster Insights Partner to Deliver Combined AI-Derived Structured Pathology and Multimodal Real-World Data Solutions

PathAI, a global leader in AI-powered pathology, and Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced a multi-year strategic partnership to develop curated multimodal datasets that pair PathAI’s PathExplore1 artificial intelligence (AI) tumor microenvironment (TME) quantification panel with Aster Insights’ Avatar clinical, molecular, and digital pathology imaging data. By combining their respective best-in-class platforms, PathAI and Aster Insights will be able to expedite the development of novel insights to accelerate the discovery and development of new treatments for patients with cancer.

Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395

Today, Owkin has unveiled its precision AI drug pipeline in oncology & immunology. To accelerate time-to-patient impact, Owkin has in-licensed OKN4395, a highly selective and potent EP2/4 dual antagonist from Idorsia that will enter Phase 1 trials in early 2025.

Unraveling the Mysteries of Protein Lipidation with Creative Proteomics

Record numbers expected at CPHI & PMEC China 2024 as Asian markets boom

Domestic and international markets in Asia surging as CPHI & PMEC China welcomes 60,000 attendees and 3500 exhibitors

Qlucore releases unique AI-based solution in the field of lung cancer subtyping

Qlucore, listed on Nasdaq First North, can now release a new version of Qlucore Insights specifically designed for the lung cancer field, with the capability to classify primary lung samples as well as metastatic lesions. The lung cancer model is being developed with Heidelberg University Hospital, supported by a Eurostars Joint European Programme grant.

Protheragen-ING Lab, a Trustworthy GLP Service Provider, Unveils Its Cutting-Edge Medical Device Services

Vaxess Announces $12M in Funding

CD Formulation Provides Genotoxic Impurity Testing Services to Detect and Evaluate the Potential of GIs for API and Drug Substances

Cresset appoints new Non-Executive Director

DrFirst Announces 2024 Healthiverse Heroes Award Winners

DrFirst Announces 2024 Healthiverse Heroes Award Winners https://www.prnewswire.com/news-releases/drfirst-announces-2024-healthiverse-heroes-award-winners-302150945.html?tc=eml_cleartime

CG Life Acquires Berry & Company Public Relations, Further Expanding Strategic Communications Services for BioPharma and Healthcare

CG Life, a science-first, tech-enabled agency, acquires Berry & Company Public Relations. The acquisition significantly expands the range of CG Life communications expertise and services to support clients in the biopharma and medical sectors.

Huateng Pharma Introduces Piroctone Olamine: A New Solution for Fungal Infections and Dandruff Control

Huateng Pharma, a leader in innovative pharmaceutical solutions, is excited to announce the launch of its latest product, Piroctone Olamine (CAS No. 68890-66-4).